SequelSEC

LIGAND PHARMACEUTICALS INC LGND

Pharmaceutical Preparations · CIK 0000886163 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$290.54M
Fiscal year ended 2026-06-30
Operating income
$94.73M
Fiscal year ended 2026-06-30
Free cash flow
$131.44M
Fiscal year ended 2026-06-30

LIGAND PHARMACEUTICALS INC (LGND) reported revenue of $290.54M and net income of $197.22M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from LIGAND PHARMACEUTICALS INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

LIGAND PHARMACEUTICALS INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$290.54M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income$94.73M
Net income$197.22M
Research & development$41.35M
Weighted-average diluted sharesUnavailable
Pretax income$237.96M
Income tax expense$40.74M
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$103.43M
Selling & marketingUnavailable

Balance

LIGAND PHARMACEUTICALS INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$1.01B
Total assets$2.19B
Current assets$1.46B
Total liabilities$1.22B
Current liabilities$46.74M
Total equity incl. NCI$967.52M
Temporary (mezzanine) equityUnavailable
Inventory$10.26M
Accounts receivable$67.01M
Goodwill$101.54M
Long-term debt$1.13B
Accounts payable$9.40M

Cash flow

LIGAND PHARMACEUTICALS INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$131.71M
Capital expenditures$278.00K
Investing cash flow-$144.78M
Financing cash flow$950.28M
Net change in cashUnavailable
Stock-based compensation$53.26M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$32.91M

Derived

LIGAND PHARMACEUTICALS INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$131.44M
Gross marginUnavailable
Operating margin32.6%
FCF margin45.2%
SBC / revenue18.3%
Current ratio31.18x
Revenue YoY growth54.9%
Net margin67.9%
R&D / revenue14.2%
CapEx / revenue0.1%
Long-term debt / equity1.16x
Effective tax rate17.1%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open LGND in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-02-27View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-09View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.